NCT02394093

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

An Open Label Crossover Pharmacokinetic Trial of Aspirin Dry Powder Versus Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To evaluate the bioavailability of a single oral dose of the Acetylsalicylic Acid containing dry powder 500 mg in comparison to the bioavailability of a single oral dose of aspirin tablets and aspirin effervescent tablets in healthy adults.

Conditions

• Pharmacology, Clinical

Interventions

Type	Name	Description
DRUG	Aspirin (Acetylsalicylic acid, BAYe4465)	One stick pack containing 500 mg acetylsalicylic acid dry powder
DRUG	Aspirin (Acetylsalicylic acid, BAYe4465)	One tablet containing 500 mg acetylsalicylic acid
DRUG	Aspirin (Acetylsalicylic acid, BAYe4465)	One effervescent tablet containing 500 mg acetylsalicylic acid

Timeline

• Start date: 2015-02-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2015-03-20
• Last updated: 2016-09-19

Locations

1 site across 1 country: United States